Novel isoform of anaplastic lymphoma kinase and its uses
AssigneeMemorial Sloan Kettering Cancer Center
InventorsPing CHI, Thomas WIESNER, Yu CHEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase (“TALK”). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing.
Claims11
-18. (canceled)
A method of determining whether an anti-cancer effect is likely to be produced in a cancer by an ALK inhibitor, comprising determining whether one or more cell of the cancer contains a detectable TALK, wherein the presence of a detectable TALK in the cell indicates that an ALK inhibitor would have an anti-cancer effect on the cancer.
A method of treating a subject having a cancer comprising:
- (a) determining whether a subject is likely to obtain therapeutic benefit from an ALK inhibitor, comprising determining whether one or more cancer cell of the subject contains a detectable TALK, wherein the presence of a detectable TALK in the cancer cell of the subject indicates that the subject is likely to benefit from an ALK inhibitor;
- and (b) treating the subject who is likely to benefit from an ALK inhibitor with a therapeutic amount of an ALK inhibitor.
A kit for determining whether an anti-cancer effect is likely to be produced in a cancer by an ALK inhibitor, comprising a means for determining the presence of a detectable TALK in one or more cell of the cancer.
Dependencies are inferred from the claim text.